NEW YORK (GenomeWeb) – AstraZeneca Singapore and Lucence Diagnostics said today that they have entered a collaboration to provide improved access to BRCA testing for women in Singapore with ovarian cancer.
Under the agreement, AstraZeneca is subsidizing testing for Singaporean women diagnosed with the disease, and Lucence will provide the testing through its clinical lab.